IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis

Balak Deepak M. W.; van Doorn Martijn B. A.; Arbeit Robert D.; Rijneveld Rianne; Klaassen Erica; Sullivan Tim; Brevard Julie; Thio Hok Bing; Prens Errol P.; Burggraaf Jacobus; Rissmann Robert

首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis

【24h】

IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis

机译：IMO-8400，一种可收费的受体7,8和9拮抗剂，证明了中度至严重的斑块牛皮癣患者的第2A期，随机，安慰剂对照试验中的临床活性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Aberrant toll-like receptors (TLRs) 7, 8, and 9 activation by self-nucleic acids is implicated in immune-mediated inflammatory diseases (IMIDs) such as psoriasis. In preclinical IMID models, blocking TLR-activation reduced disease severity. IMO-8400 is a first-in-class, oligonucleotide-based antagonist of TLRs 7, 8, and 9. We evaluated the short-term safety and proof-of-concept for efficacy of IMO-8400 in a first-in-patient phase 2 trial.

机译：None

著录项

来源
《Clinical immunology: The official journal of the Clinical Immunology Society》 |2017年第2017期|共10页
作者
Balak Deepak M. W.; van Doorn Martijn B. A.; Arbeit Robert D.; Rijneveld Rianne; Klaassen Erica; Sullivan Tim; Brevard Julie; Thio Hok Bing; Prens Errol P.; Burggraaf Jacobus; Rissmann Robert;
展开▼
作者单位

Erasmus Univ Med Ctr Dept Dermatol Rotterdam Netherlands;

Erasmus Univ Med Ctr Dept Dermatol Rotterdam Netherlands;

Idera Pharmaceut Inc Cambridge MA USA;

Ctr Human Drug Res Zernikedreef 8 NL-2333 CL Leiden Netherlands;

Ctr Human Drug Res Zernikedreef 8 NL-2333 CL Leiden Netherlands;

Idera Pharmaceut Inc Cambridge MA USA;

Idera Pharmaceut Inc Cambridge MA USA;

Erasmus Univ Med Ctr Dept Dermatol Rotterdam Netherlands;

Erasmus Univ Med Ctr Dept Dermatol Rotterdam Netherlands;

Ctr Human Drug Res Zernikedreef 8 NL-2333 CL Leiden Netherlands;

Ctr Human Drug Res Zernikedreef 8 NL-2333 CL Leiden Netherlands;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医学免疫学;
关键词
Endosomal toll-like receptors; Oligonucleotide antagonist; Type 1 interferon signaling pathway; Human beta-defensin-2; Immune-mediated inflammatory diseases; Drug-development;

机译：内体损伤的受体;寡核苷酸拮抗剂;1型干扰素信号通路;人β-defensin-2;免疫介导的炎症疾病;药物发展;

相似文献

外文文献
中文文献
专利

1. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind,placebo-controlled multicenter trial [J] . YANG Hai-zhen, LIU Xiao-ming, TU Cai-xia, 中华医学杂志（英文版） . 2012,第011期
2. Efficacy and safety of Shexiang Baoxin pill(MUSKARDIA)in patients with stable coronary artery disease:a multicenter,double-blind,placebo-controlled phase Ⅳ randomized clinical trial [J] . Jun-Bo Ge, Ying-Wu Liu, Sheng-Huang Wang, 中华医学杂志（英文版） . 2021,第002期
3. Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults:randomized,double-blind,and placebo-controlled phase 1 and phase 2 clinical trials [J] . Hong-Xing Pan, Jing-Xin Li, Dan-Dan Zhu, 中华医学杂志（英文版） . 2021,第011期
4. A double-blind,randomized,placebo- and positive-controlled phase Ⅲ trial of 1％ benvitimod cream in mild-to-moderate plaque psoriasis [J] . Lin Cai, Sen Yang, Fu-Qiu Li, 中华医学杂志（英文版） . 2020,第024期
5. IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis [J] . Balak Deepak M. W., van Doorn Martijn B. A., Arbeit Robert D., Clinical immunology: The official journal of the Clinical Immunology Society . 2017,第期

机译：IMO-8400，一种有折叠受体7,8和9拮抗剂，证明了中度至重度斑块牛皮癣患者的第2A期，随机，安慰剂对照试验中的临床活性
6. Efficacy and Safety of Toreforant, a Selective Histamine H-4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial [J] . Frankel Ellen, Song Michael, Li Shu, Journal of drugs in dermatology: JDD . 2018,第8期

机译：训练剂的功效和安全性，一种选择性组胺H-4受体拮抗剂，用于治疗中度至重度斑块的牛皮癣：相2多中心，随机，双盲，安慰剂对照试验的结果
7. Etanercept biosimilar (recombinant human tumor necrosis factor-alpha receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial [J] . Liu Lun-Fei, Chen Ji-Su, Gu Jun, Archives of dermatological research. . 2020,第6期

机译：依赖替辛生物纤维单模（重组人肿瘤坏死因子-α受体II：IgG Fc融合蛋白）和中国中度至重度斑块牛皮癣患者的甲氨蝶呤组合治疗：多期，随机，双盲，安慰剂对照试验
8. EFFECT OF TARGETED PULSED ELECTROMAGNETIC FIELD THERAPY ON CANINE POST-OPERATIVE HEMILAMINECTOMY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL [C] . ACVS Veterinary Symposium . 2018

机译：靶向脉冲电磁场治疗对犬术后血栓切除术的影响：双盲，随机，安慰剂对照临床试验
9. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
10. AB016. A double-blind placebo-controlled phase 2 trial of a novel toll-like receptor 7/8/9 antagonist (IMO-8400) in dermatomyositis [O] . Yoo Jung Kim, Elena Schiopu, Katalin Dankó, 2021

机译：AB016。一种双盲安慰剂控制的新型收费者患者7/8/9拮抗剂（IMO-8400）在皮肤病中的一种双盲安慰剂控制相2试验
11. Pharmacokinetics and Safety Profile of Bleselumab (ASKP1240) in Patients With Moderate-To-Severe Plaque Psoriasis: Results from a Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study [O] . M.S.A. Kumar, R. Tainaka, T. Zhu, 2017

机译：Bleselumab（ASKP1240）在中度至重度斑块牛皮癣患者中的药代动力学和安全型材：2A的结果，随机，双盲，安慰剂控制，顺序，多剂量升级研究
12. POC Clinical Trial for PTSD with a First-In-Class Vasopressin 1a Receptor Antagonist. [R] . Simon, N. G., Difede, J. 2017

机译：pOCD的pOC临床试验与一流的血管加压素1a受体拮抗剂。

IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis

摘要

著录项

相似文献

相关主题

期刊订阅